Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 92, Issue 3, 2011, Pages 322-328

  Kim, Mi K ^a,b   Suk, Ji H ^a   Kwon, Min J ^b   Chung, Hye S ^b   Yoon, Chang S ^b   Jun, Hye J ^b   Ko, Jung H ^b   Kim, Tae K ^b   Lee, Soon H ^b   Oh, Min K ^b   Rhee, Byoung D ^b   Park, Jeong H ^b  

^a Maryknoll Hospital   (South Korea)

^b Inje University   (South Korea)

Author keywords

Acarbose; Insulin glargine; Nateglinide; Postprandial glucose; Type 2 diabetes

Indexed keywords

4 THIAZOLIDINONE DERIVATIVE; ACARBOSE; ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN GLARGINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NATEGLINIDE; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RESPONSE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; POSTPRANDIAL STATE; PROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL;

ACARBOSE; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PHENYLALANINE; POSTPRANDIAL PERIOD; TREATMENT OUTCOME;

EID: 79957995797     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.01.022     Document Type: Article

References (34)

1. Zaccardi F., Pitocco D., Ghirlanda G. Glycemic risk factors of diabetic vascular complications: the role of glycemic variability. Diabetes Metab Res Rev 2009, 25:199-207.
2. Hanefeld M., Temelkova-Kurtshiev T. Control of post-prandial hyperglycemia-an essential part of good diabetes treatment and prevention of cardiovascular complications. Nutr Metab Cardiovasc Dis 2002, 12:98-107.
3. Gerich J.E. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 2003, 163:1306-1316.
4. Ceriello A., Hanefeld M., Leiter L., Monnier L., Moses A., Owens D., et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004, 164:2090-2095.
5. Heine R.J., Balkau B., Ceriello A., Del Prato S., Horton E.S., Taskinen M.R. What does postprandial hyperglycaemia mean?. Diabet Med 2004, 21:208-213.
6. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001, 161:397-405. DECODE Study Group, the European Diabetes Epidemiology Group.
7. Meigs J.B., Nathan D.M., D'Agostino R.B., Wilson P.W. Framingham Offspring Study. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002, 25:1845-1850.
8. Shiraiwa T., Kaneto H., Miyatsuka T., Kato K., Yamamoto K., Kawashima A. Postprandial hyperglycemia is a better predictor of the progression of diabetic retinopathy than HbA1c in Japanese type 2 diabetic patients. Diabetes Care 2005, 28:2806-2807.
9. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat?. Diabetes 2005, 54:1-7.
10. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003, 290:486-494.
11. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus: DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997, 314:1512-1515.
12. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R.S., et al. Medical management of hyperglycemia in type2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
13. Baxter M.A. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes. Acta Diabetol 2008, 45:253-268.
14. Haimoto H., Sasakabe T., Umegaki H., Wakai K. Acute metabolic responses to a high-carbohydrate meal in outpatients with type 2 diabetes treated with a low-carbohydrate diet: a crossover meal tolerance study. Nutr Metab (Lond) 2009, 6:52-60.
15. Landgraf R. The relationship of postprandial glucose to HbA1c. Diabetes Metab Res Rev 2004, 20:S9-S12.
16. Monnier L., Lapinski H., Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care 2003, 26:881-885.
17. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 1998, 19:477-490.
18. Lillioja S., Mott D.M., Spraul M., Ferraro R., Foley J.E., Ravussin E., et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of Pima Indians. N Engl J Med 1993, 329:1988-1992.
19. Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002, 287:360-372.
20. Ristic S., Collober-Maugeais C., Cressier F., Tang P., Pecher E. Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results. Diabetes Obes Metab 2007, 9:506-511.
21. Feinböck C., Luger A., Klingler A., Egger T., Bielesz G.K., Winkler F., et al. Prospective multicentre trial comparing the efficacy of, and compliance with, glimepiride or acarbose treatment in patients with type 2 diabetes not controlled with diet alone. Diabetes Nutr Metab 2003, 16:214-221.
22. Chiasson J.L., Josse R.G., Hunt J.A., Palmason C., Rodger N.W., Ross S.A., et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994, 121:928-935.
23. Service F.J., Molnar G.D., Rosevear J.W., Ackerman E., Gatewood L.C., Taylor W.F. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970, 19:644-655.
24. Kovatchev B.P., Otto E., Cox D., Gonder-Frederick L., Clarke W. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care 2006, 29:2433-2438.
25. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
26. Duran C., Tuncel E., Ersoy C., Ercan I., Selimoglu H., Kiyici S., et al. The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese type 2 diabetic patients. J Endocrinol Invest 2009, 32:69-73.
27. Van Gaal L.F., De Leeuw I.H. Rationale and options for combination therapy in the treatment of type 2 diabetes. Diabetologia 2003, 46:M44-M50.
28. Shiba T. Improvement of insulin resistance by a new insulin secretagogue, nateglinide-analysis based on the homeostasis model. Diabetes Res Clin Pract 2003, 62:87-94.
29. Li J., Tian H., Li Q., Wang N., Wu T., Liu Y., et al. Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial. Diabetes Obes Metab 2007, 9:558-565.
30. Hazama Y., Matsuhisa M., Ohtoshi K., Gorogawa S., Kato K., Kawamori D., et al. Beneficial effects of nateglinide on insulin resistance in type 2 diabetes. Diabetes Res Clin Pract 2006, 71:251-255.
31. Yoshihara T., Kumashiro N., Kanazawa Y., Mita T., Sakurai Y., Kawai J., et al. Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus. Endocr J 2006, 53:67-72.
32. Schnack C., Prager R.J.F., Winkler J., Klauser R.M., Schneider B.G., Schernthaner G. Effects of 8-wk α-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients. Diabetes Care 1989, 12:537-543.
33. Johnson A.B., Taylor R. Does suppression of postprandial blood glucose excursions by the α-glucosidase inhibitor miglitol improves insulin sensitivity in diet-treated type II diabetic patients?. Diabetes Care 1996, 19:559-563.
34. Hirose T., Miyashita Y., Takagi M., Sumitani S., Kouhara H., Kasayama S. Characteristics of type 2 diabetic patients responding to voglibose administration as an adjunct to sulfonylurea. Diabetes Res Clin Pract 2001, 54:9-15.